如何加速向全球所有人群供应疫苗?第三部分:大流行后的反思
本文讨论加速大流行防范的努力,并报告疫苗生产商对早期与后期大流行经验的比较评估。从合作性大流行路径转向严格的非大流行要求可能影响供应,仍需要灵活性与依赖机制以确保产品及时可及。
要点
- 大流行期间的合作与成功证明了简化要求和依赖机制的好处。
- 从合作性大流行路径转向严格的非大流行要求可能影响供应。
- 仍需要灵活性与依赖机制以确保产品及时可及。
核心结论
- 从合作性大流行路径转向严格的非大流行要求可能影响供应。
- 仍需要灵活性与依赖机制以确保产品及时可及。
- 本文强调继续大流行防范并基于经验教训采取行动的重要性。
研究设计与样本
- 本文讨论加速大流行防范的努力,并报告疫苗生产商对早期与后期大流行经验的比较评估。
主要发现
- 大流行期间展示的合作与成功证明了简化要求和依赖机制的好处。
- 疫苗开发者、生产商、流行病防范创新联盟(CEPI)及其他利益相关方已参与讨论,以突出从该经验中吸取的教训并寻找解决这些挑战的方案。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
When the Covid-19 pandemic was declared by WHO, a team of vaccine manufacturers worked with the COVAX (COVID-19 Vaccine Global Access) Manufacturing SWAT (Support Work to Advance) team to propose regulatory agilities for accelerating access to vaccines. The cooperation and success demonstrated during the pandemic demonstrated the benefits of simplifying requirements and reliance. Vaccine developers, manufacturers, the Coalition for Epidemic Preparedness Innovations (CEPI), and other stakeholders have engaged in discussions to highlight the lessons learned from this experience and to find solutions to address those challenges. This paper discusses efforts to accelerate pandemic preparedness and reports a comparative assessment of early and later pandemic experiences from vaccine manufacturers. The lessons learned and the risk-based approaches were invaluable in bringing vaccines to patients. However, the shift from cooperative pandemic pathways to strict non-pandemic requirements can impact supply. Flexibility and reliance are still needed to ensure timely product availability. This article emphasizes the importance of continuing pandemic preparedness and acting on lessons learned.
引用
- McGoldrick M, Truong TBQ, Campa C, et al. How to accelerate the supply of vaccines to all populations worldwide? Part III: Reflections after the pandemic. Vaccine. 2025. PMID: 39892115. doi:10.1016/j.vaccine.2025.126782
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。